Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today hosted its 2025 Investor Day at the...
Business Wire·5h ago
More News
Peering Into Insulet Corp's Recent Short Interest
read more...
Benzinga·7h ago
3 Stocks With Upgraded Broker Ratings to Buy for Solid Returns
Upgraded broker ratings bring the spotlight to PODD, SNDK and OI as potential picks in a selective market, each showing strong earnings growth and momentum.
Zacks·11h ago
$1000 Invested In Insulet 15 Years Ago Would Be Worth This Much Today
read more...
Benzinga·1d ago
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Mitsubishi UFJ Trust & Banking Corp reduced its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 63.4% during the second quarter, according to its most recent filing with the SEC. The fund...
MarketBeat·2d ago
Zacks Industry Outlook Highlights Boston Scientific, Insulet, BioLife Solutions and Allurion
Boston Scientific, Insulet, BioLife Solutions and Allurion push ahead with innovation and efficiency as the Medical Products industry faces pressure.
Zacks·3d ago
Do Options Traders Know Something About Insulet Stock We Don't?
Investors need to pay close attention to PODD stock based on the movements in the options market lately.
Zacks·3d ago
4 Medical Product Stocks to Watch From a Challenging Industry
The Zacks Medical products industry sees steady demand, but macro headwinds keep growth under pressure in 2025. BSX, PODD, BLFS and ALUR reflect the favorable fundamentals.